The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
FlamMMadhuJPajakTF. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;4(9):2527–2539.
3.
BartelinkHRoelofsenFEschwegeF. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–2049.
4.
BasserRLSmithJGWorotniukVGuineyMJ. Conservative management of squamous cell carcinoma of the anal canal. Aust NZ J Surg. 1994;64(11):754–758.
5.
CummingsBJKeaneTJO'SullivanB. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–1125.
6.
CummingsBJKeaneTJO'SullivanB. Mitomycin in anal carcinoma. Oncology. 1993;50(1):63–69.
7.
KappKSKappDSStuecklschweigerGBergerAGeyerE.Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study. Int J Radiat Oncol Biol Phys. 1993;28(1):189–199.
8.
VuongTDevicSBelliveauPMuanzaTHegyiG.Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys. 2003;56(3):823–831.
9.
BossetJFRoelofsenFMorganDAL. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer. 2003;39(1):45–51.
10.
RaffettoNMonacoABanelliE.Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. Anticancer Res. 2008;28(2B):1335–1340.
11.
DociRZucaliRBombelliL. Combined chemoradiation therapy for anal cancer. A report of fifty-six cases. Ann Surg. 1992;215(2):150–156.
12.
AjaniJWinterKGundersonL. Fluorouracil, mitomycin, and radiotherapy versus fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal, a randomized controlled trial. JAMA. 2008;299(16):1914–1921.
13.
MatzingerORoelofsenFMineurL. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organization for Research and Treatment of Cancer Phase II Study 22011-40014). Eur J Cancer. 2009;45(16):2782–2791.
MarounJAAnthonyLBBlaisN. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14(1):13–20.
18.
BensonABAjaniJACatalanoRB. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–2926.
19.
KintzelPEDorrRT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33–64.
20.
BoyiadzisMMLebowitzPFFrameJNFojoT.Hematology-Oncology Therapy. New York: McGraw-Hill; 2007:570–578.
21.
KingPDPerryMC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6:162–176.
22.
FloydJMirzaISachsBPerryMC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33:50–67.
